Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma
about
Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathwayIdentification of a shared genetic susceptibility locus for coronary heart disease and periodontitisNext generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor targetAssociations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutationsLong Non-coding RNA ANRIL and Polycomb in Human Cancers and Cardiovascular DiseasePromoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinomaStrong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-cateninSelective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines.Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.Expression of Hugl-1 is strongly reduced in malignant melanoma.Functional modulation of IGF-binding protein-3 expression in melanomaAberrant DNA methylation in malignant melanomaVariants at the 9p21 locus and melanoma riskGermline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in MiceGenome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous neviExpression of MTAP inhibits tumor-related phenotypes in HT1080 cells via a mechanism unrelated to its enzymatic function.Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.Immunohistochemistry in melanocytic proliferative lesions.EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.Characterization of the Methylthioadenosine Phosphorylase Polymorphism rs7023954 - Incidence and Effects on Enzymatic Function in Malignant MelanomaEpigenetic events in malignant melanoma.A potential predictive marker for response to interferon in malignant melanoma.Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanomaCharacterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategiesSuppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cellsMetabolic Hallmarks of Tumor and Immune Cells in the Tumor MicroenvironmentGenomic Study of Cardiovascular Continuum Comorbidity.Are STATS arginine-methylated?Promoter methylation profiling of 30 genes in human malignant melanoma.Analysis of p16 expression and allelic imbalance / loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas.Regulation of human methylthioadenosine phosphorylase gene by the CBF (CCAAT binding factor)/NF-Y (nuclear factor-Y)Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma.Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma.A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
P2860
Q21133782-A99A6FC2-D0A9-40FF-9080-0A820279456CQ21563349-0B4E6F5F-CB6F-41E3-BD6D-34548D3ED042Q24608574-B9ABEBAB-A14C-489B-9522-669F638B627BQ24630954-E883B156-3737-4D94-9AEB-D15A901BB570Q26798251-9F5CBB7D-9928-424F-A4D7-3C39C926D66BQ28265788-E1C89AA7-68F2-4C78-9CDD-FFB3EAB4F6BCQ28288573-CF876594-231C-4CBA-A459-24E427771A90Q33455616-6BD2AA06-A81E-48F1-BE84-8B137852B71DQ34012561-D831DFAA-D095-4C9D-B75C-9797E2D25B43Q34098773-E8AEB838-7CDD-42A7-B75A-DC584F9F1FCAQ34451983-DE7BE7A2-E58D-4D42-AE9C-D594A6BAC165Q34505279-BF13E530-C4EC-4F73-9DAC-AA8A05B1094DQ34516587-1562DB39-9786-4FC6-B8C1-647E7D47B5CAQ34788513-6FA04531-70CB-43D3-8CAA-FA24077F0621Q34807817-1F292935-82A9-4DBC-9392-033603F19D2EQ34831505-69D6812B-22A2-4FEC-BCA7-6ADA179005DAQ34923845-4320F6F4-A341-41EE-B788-B754890B1252Q34956745-C4DDE811-A432-4047-8B40-96812919D13AQ35770092-239DBA02-C786-4D77-97FC-EFD3C92A6B3AQ35798186-14C9BD18-8A09-4928-9E43-E19FCF065C75Q35849977-0F25A529-B442-4F91-AFC2-97CC36BBCAFEQ36091672-5E06CF30-0ECC-430A-A25C-6AEA6175CE64Q36764224-E44F6309-93A5-4BDD-9886-BCA4E242FD40Q36835008-2B3058A9-CC22-45E3-92BE-1F8ECAB33022Q36930013-215BEE66-5AFA-43DF-8D4D-CCF7F1FD7D3DQ37226083-16AD7868-9B09-488B-BBBD-4DAD15CB8DBDQ37375149-1AAA5474-7115-4476-9C8F-F7642112F587Q37837359-0009EB03-9DCA-4E9F-96BA-09AB204E0DF8Q38746611-BCFAF2E1-1A16-4B2A-BE3A-48D8765EE924Q39197674-77EF4D53-7F1F-438E-BC0E-D0FF70F4199CQ40412731-BC6A2C7F-B43E-4180-8DA7-BE21002844A9Q40436094-4E0A1CCC-1E0A-44AC-B233-D323E9B5C3FCQ40481342-33FCA471-71B7-4E45-88D2-0DF925201975Q41815800-4D719886-B986-4396-8E57-412C2601E197Q42062520-3BF73337-A247-4577-A4AC-95FBE264D701Q42415481-B2FA7A2D-BCEF-436A-9CBD-CC25B9A5C17FQ42426159-0552834C-7720-4181-A23B-16A38704F401Q43054803-00F02BE5-E3C3-46EC-B63E-99CFEFD502E4Q46190030-9326B975-80C8-42F1-B0C6-B75629514267Q46490111-6CE4BCA7-1A6D-4BD6-A57E-411EE3D2407F
P2860
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Characterization of methylthio ...... pression in malignant melanoma
@ast
Characterization of methylthio ...... pression in malignant melanoma
@en
Characterization of methylthio ...... pression in malignant melanoma
@nl
type
label
Characterization of methylthio ...... pression in malignant melanoma
@ast
Characterization of methylthio ...... pression in malignant melanoma
@en
Characterization of methylthio ...... pression in malignant melanoma
@nl
prefLabel
Characterization of methylthio ...... pression in malignant melanoma
@ast
Characterization of methylthio ...... pression in malignant melanoma
@en
Characterization of methylthio ...... pression in malignant melanoma
@nl
P2093
P2860
P3181
P1476
Characterization of methylthio ...... pression in malignant melanoma
@en
P2093
Anja-Katrin Bosserhoff
Iris Behrmann
Marion Schuierer
Peter C Heinrich
Reinhard Buettner
Susanne Wallner
Waraporn Komyod
P2860
P304
P3181
P356
10.1016/S0002-9440(10)63695-4
P407
P577
2003-08-01T00:00:00Z